YOUNESS OUAHID BENKADDOUR

AtG Therapeutics has developed a novel oncology platform to outsmart resistant cancer by targeting tumor adaptation—one of the key mechanisms driving treatment failure. Our approach centers on inhibiting Tumor Adaptation Factor 1 (TA-1), an enzyme overexpressed in aggressive, therapy-resistant tumors. AtG is advancing a portfolio of potent, orally available small molecules that selectively inhibit TA-1, disrupting cancer’s ability to survive under therapeutic stress. This strategy exploits adaptive synthetic lethality: while TA-1 inhibition is harmless to normal cells, it becomes lethal to cancer cells that rely on tumor reprogramming for survival. Designed for use across multiple solid tumors—including renal and colorectal cancers—our therapy is supported by a companion plasma biomarker in development to identify patients most likely to respond, enabling truly personalized treatment